What is NovoCure's stock issuance proceeds?

NovoCure (NVCR) reported stock issuance proceeds of $0 in Q1 2026.

What is the long-term trend for NovoCure's stock issuance proceeds?

Over 4 years (2021 to 2025), NovoCure's stock issuance proceeds has grown at a -5.3% compound annual growth rate (CAGR), from $4.55M to $3.66M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

NovoCure NVCR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

MedtronicMDT

$97M-10.2%

Iovance Biotherapeutics, Inc.IOVA

$98.51M-33.9%

Nuvation BioNUVB

$908K-16.1%

ArriVent BioPharma, Inc.AVBP

$54.72M+740%

Ethos Technologies, Inc. LIFE

$0-100%

Tango TherapeuticsTNGX

$17.61M+880,150%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's stock issuance proceeds?: NovoCure (NVCR) reported stock issuance proceeds of $0 in Q1 2026.
What is the long-term trend for NovoCure's stock issuance proceeds?: Over 4 years (2021 to 2025), NovoCure's stock issuance proceeds has grown at a -5.3% compound annual growth rate (CAGR), from $4.55M to $3.66M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.